Navigation Links
Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
Date:10/21/2011

the company and its product pipeline to investors on a conference call. To participate in the conference call, please call one of the following telephone numbers 15 minutes prior to the event, using access code 6749807: +31(0)20-721-9158 for the Netherlands and +44(0)20-3450-9987 for the UK. Following the presentation, the lines will be opened for questions. A replay of the call will be available following the event.

About Glybera®

AMT has developed Glybera as a treatment for patients with the genetic disorder lipoprotein lipase deficiency. LPLD is an orphan disease for which no treatment exists today. The disease is caused by mutations in the LPL gene, resulting in highly decreased or absent activity of LPL protein in patients. This protein is needed in order to break down large fat-carrying particles that circulate in the blood after each meal. When such particles, called chylomicrons, accumulate in the blood, they may obstruct small blood vessels. Excess chylomicrons result in recurrent and severe acute inflammation of the pancreas, called pancreatitis, the most debilitating and life-threatening clinical complication of LPLD. Glybera® has orphan drug status in the EU and US.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. In addition to Glybera, AMT has a product pipeline of several gene therapy products in development for hemophilia B, Duchenne muscular dystrophy, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... President and Chief Executive Officer, will present live ... DATE:  Thursday, May 7, 2015     TIME:  11:30 am ET/8:30 ... click the red "register/ watch presentations" button ... event where investors are invited to ask the ...
(Date:5/5/2015)... DUBLIN , May 05, 2015 Research ... announced the addition of the "Clinical Laboratory, ... and Forecasts 2015 to 2019 - Europe Version" ... technical developments especially in the area of molecular ... dynamic, growing and evolving world market that is ...
(Date:5/5/2015)... Station, TX (PRWEB) May 05, 2015 ... were announced last week as recipients of the ... Innovation in recognition of their Portable, Continuous, Miniature ... that integrates a small footprint, continuous processing equipment, ... modules) to process API powders and inactive ingredients ...
(Date:5/4/2015)... May 4, 2015 Tobira Therapeutics, Inc. ... the development and commercialization of novel treatments for ... of its merger with Regado Biosciences, Inc. (NASDAQ: ... closing of the merger, Tobira raised $40 million ... investors and all current Tobira institutional investors, including ...
Breaking Biology Technology:ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2European Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market 2015-2019 2GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 2GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 3Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 2Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 3Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 4Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 5Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 6
... 23, 2010 In a world where millions suffer daily ... out as the definitive leader in natural, safe and effective ... Now, patients are raving about the amazing results of the ... (Menstrual) is the first of its kind supplement ...
... 23, 2010 HRC Medical Center is passionate about ... the most technologically advanced methods of Bio-Identical Hormone Therapy ... energy, depression, decreased sex drive, memory loss, anxiety, joint ... of muscle tone, chances are you may have a ...
... COLLEGE PARK, Md., Dec. 23, 2010 Martek Biosciences, ... Institute (Mtech) at the University of Maryland, entered an ... Dutch company Royal DSM NV for $1.1 billion, the ... Martek is the second company sold ...
Cached Biology Technology:A Breakthrough for Migraines, PMS and PCOS! 2HRC Medical Center Offers Patients Relief with Innovative Bio-Identical Hormone Replacement Therapy 2Martek Is Second Mtech Company Sold for More Than $1 Billion in Three Years 2Martek Is Second Mtech Company Sold for More Than $1 Billion in Three Years 3Martek Is Second Mtech Company Sold for More Than $1 Billion in Three Years 4
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
(Date:3/23/2015)... BOSTON, Mass , March 23, 2015 SoundView ... shipment of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView ... world user feedback on their experience with the Wocket in ... experience at CVS, Whole Foods and other retailers, making both ... Kris Tuttle also says, "If the company meets ...
(Date:3/20/2015)... Mar. 20, 2015 Research and Markets ... of the "India Sensors Market Forecast and ... The sensor market is projected to grow ... Consumer electronics, automotive, industrial and healthcare sectors ... the country. In addition, adoption of MEMS technology ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... cousin of the bacterium that debilitated thousands of World War ... who had been on an international vacation. The woman, who ... typhoid fever, two infections that can occur in returning travelers. ... was infected with a new bacterium that had never before ...
... a single protein with an experimental drug prevented and ... mice that had been fed unhealthy diets and were ... article published online at Nature on June 6, 2007. ... chair of the Department of Genetics and Complex Diseases ...
... new clues to a very cold case: the disappearance of ... all Ice Age giants, according to a June 7th report ... , DNA lifted from the bones, teeth, and tusks of ... expansion after the last interglacial period. After the mammoths’ migration, ...
Cached Biology News:New bacterium discovered -- related to cause of trench fever 2New bacterium discovered -- related to cause of trench fever 3New bacterium discovered -- related to cause of trench fever 4In mice, drug protects against diabetes and atherosclerosis 2In mice, drug protects against diabetes and atherosclerosis 3In mice, drug protects against diabetes and atherosclerosis 4Ancient DNA traces the woolly mammoth's disappearance 2